CSN Login
Members Online: 5

You are here

Update phase 1 trial Arry-438162

cyndi2324's picture
cyndi2324
Posts: 72
Joined: Oct 2009

My phase 1 trial Arry-438162, 2nd and 3rd week. The 23rd of Nov. I had another long day at the research center lots of labs ecg. at different times through out the day after taking a dose of drug. So far my labs are good. I started getting a rash on the lower half of my face by the end of that day. I was still having some pain about a level 3-4 at different times during the day. I had already noticed that my pain went away for a while after taking the drug.
By the end of this week my rash had gotten much worse. It was in my ears on my head and on more of my face. It burned and looked AWFUL. I had started taking 25mg Benadryl about every 4 hrs. The Dr. put me on an antibiotic and lotion (YEA) which is helping a lot. The rash is drying up it looks a lot better. My energy level is GOOD and other that the rash and a little diarrhea I’m ok.
The really interesting thing for me is since this Mon. I have been pain FREE. I have no clue what that means in regards to my cancer and the drug, but I’m enjoying no pain. I still have some rash but nothing like it was before. The men taking the same drug that I’m taking are having a rash on their chest and back. I don’t know what that means. They are checking my vision tomorrow, then I go back Mon. to pick up more of the pills. They are going to do a follow up CT on me Dec. 23rd to look for changes in my mets. I hope that something good is going on with me and this drug.
You all Take Care,
Cyndi

damama24
Posts: 175
Joined: Nov 2009

I will pray that this new medication works wonders for you. Sorry to hear about the side effects but you seem to be handeling them well. I am also in a clinical trial with a new med and am hoping it works wonders for me and others in the future. Stay positive and fight the good fight. We are all here for you. Deb

cyndi2324's picture
cyndi2324
Posts: 72
Joined: Oct 2009

Thanks Deb, I hope you have a good response to your trial. I said a prayer for you also. I will KEEP FIGHTING.
Cyndi

Kathleen808's picture
Kathleen808
Posts: 2361
Joined: Jan 2009

Cyndi,
It is good to hear that your pain is gone. Thanks for keeping us updated on the trial. This info can end up being so helpful to others. I believe people have learned so much on this board because of people like you who are willing to share. Best to you.

Aloha,
Kathleen

linandtom
Posts: 67
Joined: Dec 2009

Our doctor discussed ARRY-438162 with us today. Do you mind telling us how your CT scans looked? Good news I hope? Not sure if we should try this study or move on and find something else. Looking forward to hearing from you if you don't mind discussing. Thanks Cyndi2324

lisa42's picture
lisa42
Posts: 3661
Joined: Jul 2008

Hi Cyndi and Linda,

Cyndi,
It would be great to hear an update since you last wrote a month ago, on how you're doing now. Although I'm on an alternative treatment of lovastatin and interferon from Dr. Cantrell and have great hopes for it, I still feel like I need to have some things on the "back burner" just in case this treatment doesn't give me the desired effects. I have no reason to think it won't help at this point & am actually feeling very optimistic about it, but I think it's always good to be prepared. With that said, I'd love to hear more details about what the ARRY-438162 clinical trial involves- what the drugs are, where you're going for treatment, and any other details you'd care to share. How is the rash? What drug was causing the rash?

Thanks in advance & hope you are doing well-
Lisa

cyndi2324's picture
cyndi2324
Posts: 72
Joined: Oct 2009

I have 4 mets in abdoman none in colon (cut out) I in euteras(too tired to spell or care) 2 the largest below belly button close to front surface old scare stuff painful3 inthe front part of messentic ? 4 on top of psoas muscle. I need to get a second opinon if I can find someone here to give me one,I think mine might need Da Vici knife or Radio frequency thing or both. I your Dr, Has a sugestion please let me know. I don't have any in bone, liver, lung, or brain although my Dr calls it a metastasized sage 4 colon cancer, I also have s colostomy and am a kras mutant originally dig. 2008.
This is were I go http://www.startthecure.com/news_2009.html
This is supose to be one of the HOT NEW STUDIES:01/05/10
FIRST PATIENT ENROLLED IN PHASE I CLINICAL TRIAL OF LANDMARK ASTRAZENECA, MERCK & CO. NOVEL
COMBINATION ANTICANCER REGIMEN. START Center for Cancer Care in San Antonio, announced today that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. and AZD6244 (ARRY-886*) from AstraZeneca. Anthony Tolcher, clinical director for START, and principal investigator for this trial said, “This one-of-a-kind study, with two separate pharmaceutical companies sharing their novel agents for this one clinical trial performed at START, represents an exciting step forward for the betterment of cancer research, and most of all, patient care.”

Background On The Two Anticancer Agents (compiled from information contained in the companies’ original release on the collaboration)
Each candidate is designed to inhibit a protein known to be abnormally activated in human cancers. In preclinical studies, AZD6244 has been shown to affect MEK (Mitogen-activated protein kinase 1), an important signal that promotes cancer cell growth and survival. AZD6244 has completed Phase I evaluation, demonstrating proof of mechanism, and several Phase II monotherapy studies, which showed evidence of clinical activity. It is currently in Phase II clinical trials in a range of tumor types. Merck’s MK-2206 has demonstrated an effect on AKT (a component of the phosphatidylinositol-3 kinase pathway), an important signal promoting cancer cell survival.
Advances in cancer research have led to a new generation of drugs designed to precisely target features specific to cancer cells while minimizing the effect on healthy cells. Several of these drugs provide patient benefit as monotherapy, but increasingly the ability of cancer cells to adapt and develop resistance has become apparent. Research suggests that combination therapies that include drugs with different mechanisms of action impacting cancer cells in multiple ways may provide an improved anticancer benefit and decrease the risk of relapse.

Molecular profiling of human solid tumors has shown that both the MEK and AKT pathways are frequently abnormally activated. Preclinical studies have suggested that simultaneously inhibiting both of these pathways may have synergistic effects on tumor cell growth.

Patients wishing more information about the study should call Tracy Dufresne, patient referral coordinator for START at 210-593-5265.
###

My Arry study didn't for me don't know if because of k-ras mutated gene or something else. If I could I get in the AZD6244 and the merck drug. See if your Dr. can help if he or she thinks it might help, As of 1-6-10 this was open I think Although the NIC web site said it was open THE National cancer Institut= http://www.cancer.gov/ =ProtocalID 2009-698 MK2206010 NCT0121748
Good Luck and God Bless I will send more info when I get to feeling better bye Cyndi (sqweeky wheel gets the grease, This is all I can do now my eys are crossing

cyndi2324's picture
cyndi2324
Posts: 72
Joined: Oct 2009

Lisa I hope you can read this n\as Im VERY TIRED an\d have a treatment @ 9am 1.5 hours from here. God Bless YUO
I have 4 mets in abdoman none in colon (cut out) I in euteras(too tired to spell or care) 2 the largest below belly button close to front surface old scare stuff painful3 inthe front part of messentic ? 4 on top of psoas muscle. I need to get a second opinon if I can find someone here to give me one,I think mine might need Da Vici knife or Radio frequency thing or both. I your Dr, Has a sugestion please let me know. I don't have any in bone, liver, lung, or brain although my Dr calls it a metastasized sage 4 colon cancer, I also have s colostomy and am a kras mutant originally dig. 2008.
This is were I go http://www.startthecure.com/news_2009.html
This is supose to be one of the HOT NEW STUDIES:01/05/10
FIRST PATIENT ENROLLED IN PHASE I CLINICAL TRIAL OF LANDMARK ASTRAZENECA, MERCK & CO. NOVEL
COMBINATION ANTICANCER REGIMEN. START Center for Cancer Care in San Antonio, announced today that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. and AZD6244 (ARRY-886*) from AstraZeneca. Anthony Tolcher, clinical director for START, and principal investigator for this trial said, “This one-of-a-kind study, with two separate pharmaceutical companies sharing their novel agents for this one clinical trial performed at START, represents an exciting step forward for the betterment of cancer research, and most of all, patient care.”

Background On The Two Anticancer Agents (compiled from information contained in the companies’ original release on the collaboration)
Each candidate is designed to inhibit a protein known to be abnormally activated in human cancers. In preclinical studies, AZD6244 has been shown to affect MEK (Mitogen-activated protein kinase 1), an important signal that promotes cancer cell growth and survival. AZD6244 has completed Phase I evaluation, demonstrating proof of mechanism, and several Phase II monotherapy studies, which showed evidence of clinical activity. It is currently in Phase II clinical trials in a range of tumor types. Merck’s MK-2206 has demonstrated an effect on AKT (a component of the phosphatidylinositol-3 kinase pathway), an important signal promoting cancer cell survival.
Advances in cancer research have led to a new generation of drugs designed to precisely target features specific to cancer cells while minimizing the effect on healthy cells. Several of these drugs provide patient benefit as monotherapy, but increasingly the ability of cancer cells to adapt and develop resistance has become apparent. Research suggests that combination therapies that include drugs with different mechanisms of action impacting cancer cells in multiple ways may provide an improved anticancer benefit and decrease the risk of relapse.

Molecular profiling of human solid tumors has shown that both the MEK and AKT pathways are frequently abnormally activated. Preclinical studies have suggested that simultaneously inhibiting both of these pathways may have synergistic effects on tumor cell growth.

Patients wishing more information about the study should call Tracy Dufresne, patient referral coordinator for START at 210-593-5265.
###

My Arry study didn't for me don't know if because of k-ras mutated gene or something else. If I could I get in the AZD6244 and the merck drug. See if your Dr. can help if he or she thinks it might help, As of 1-6-10 this was open I think Although the NIC web site said it was open THE National cancer Institut= http://www.cancer.gov/ =ProtocalID 2009-698 MK2206010 NCT0121748
Good Luck and God Bless I will send more info when I get to feeling better bye Cyndi (sqweeky wheel gets the grease, This is all I can do now my eys are crossing

cyndi2324's picture
cyndi2324
Posts: 72
Joined: Oct 2009

This is were Igo http://www.startthecure.com/news_2009.html
This is supose to be one of the HOT NEW STUDIES:01/05/10
FIRST PATIENT ENROLLED IN PHASE I CLINICAL TRIAL OF LANDMARK ASTRAZENECA, MERCK & CO. NOVEL
COMBINATION ANTICANCER REGIMEN. START Center for Cancer Care in San Antonio, announced today that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. and AZD6244 (ARRY-886*) from AstraZeneca. Anthony Tolcher, clinical director for START, and principal investigator for this trial said, “This one-of-a-kind study, with two separate pharmaceutical companies sharing their novel agents for this one clinical trial performed at START, represents an exciting step forward for the betterment of cancer research, and most of all, patient care.”

Background On The Two Anticancer Agents (compiled from information contained in the companies’ original release on the collaboration)
Each candidate is designed to inhibit a protein known to be abnormally activated in human cancers. In preclinical studies, AZD6244 has been shown to affect MEK (Mitogen-activated protein kinase 1), an important signal that promotes cancer cell growth and survival. AZD6244 has completed Phase I evaluation, demonstrating proof of mechanism, and several Phase II monotherapy studies, which showed evidence of clinical activity. It is currently in Phase II clinical trials in a range of tumor types. Merck’s MK-2206 has demonstrated an effect on AKT (a component of the phosphatidylinositol-3 kinase pathway), an important signal promoting cancer cell survival.
Advances in cancer research have led to a new generation of drugs designed to precisely target features specific to cancer cells while minimizing the effect on healthy cells. Several of these drugs provide patient benefit as monotherapy, but increasingly the ability of cancer cells to adapt and develop resistance has become apparent. Research suggests that combination therapies that include drugs with different mechanisms of action impacting cancer cells in multiple ways may provide an improved anticancer benefit and decrease the risk of relapse.

Molecular profiling of human solid tumors has shown that both the MEK and AKT pathways are frequently abnormally activated. Preclinical studies have suggested that simultaneously inhibiting both of these pathways may have synergistic effects on tumor cell growth.

Patients wishing more information about the study should call Tracy Dufresne, patient referral coordinator for START at 210-593-5265.
###

My Arry study didn't for me don't know if because of k-ras mutated gene or something else. If I could I get in the AZD6244 and the merck drug. See if your Dr. can help if he or she thinks it might help, As of 1-6-10 this was open I think Although the NIC web site said it was open THE National cancer Institut= http://www.cancer.gov/ =ProtocalID 2009-698 MK2206010 NCT0121748
Good Luck and God Bless I will send more info when I get to feeling better bye Cyndi (sqweeky wheel gets the grease, This is all I can do now my eys are crossing

Subscribe to Comments for "Update phase 1 trial  Arry-438162"